Redefining Targeted Therapy: Bispecific T-Cell Engagers and Antibody-Drug Conjugates 2

• 5388 Dual targeting of CEACAM6 and EGFR with a bispecific antibody induces EGFR degradation and overcomes anti-EGFR resistance Ming-Heng Wu, Chee Voon Yap, Yao-Tsung Tsai
• 5389 CC312, a novel CD19/CD3/CD28 tri-specific T cell engager, leads to rapid and deep B-cell depletion and has broad potential for development in autoimmune diseases Mingyuan Sun, Yingfeng Huang, Ruixia Zhang, Zhen Jing, Xiaofang Zhang, Yuchao Wei, Junyuan Qi
• 5390 · PDF Mechanistic drivers of FAP-targeted ADC performance Atanasio Pandiella, Monica Redondo-Puente, Maria del Carmen Gomez-Garcia, Patricia Gonzalez, Isabel Egaña, Roland Kontermann, Oliver Seifert, Jorge Galino, Sonia Montero-Molina, Jose Luis Hernandez, Juan Daniel Sanjuan, Guillermo Quintas, Ignacio Garcia, Manuel Hidalgo, Laureano Simon, Myriam Fabre
• 5391 A versatile KY-HC-mouse™nanobody platform enabling tumor-anchored, conditionally active 4-1BB bispecific antibodies Xiaoting Liang, Siyu Li, Jie Xu, Hao Peng, Feng Hao, Jinying Ning
• 5392 · PDF Targeting solid tumors with pH-dependent dual-specific TCEs: First-in-human development of CT-202 Stanley Roberts, Kelly Byrnes-Blake, Heather Ansorge, Eric Butz, Daniel Olson
• 5393 · PDF Preclinical efficacy and safety profile of NPX125, a novel ADC targeting B7-H7 Silvia Ferrati, Emilien Loeuillard, Susannah L. Hewitt, Matthew Peter Rausch, Bijan Etemad-Gilbertson, Jamie Strand, Riale Gilligan, Katalin Kis-Toth, Yasmin Hashambhoy-Ramsay, Emma Wang, Leena Gandhi, Tatiana Novobrantseva
• 5394 Novel multispecific T cell engagers exploit avidity for highly selective targeting of B-myeloid mixed-phenotype acute leukemia Sophie Jamet, Huiyuan Zhang, Ray Ruff, Irene Chen, Sally Ditzler, Kiersten Tucker, Hailey Hentschel, Jessica Chantel Ramadhin, James M. Olson, Jason Price, Mignon L. Loh
• 5397 A novel anti-CD3×CD28×STEAP1 tri-specific T-cell engager with enhanced and durable antitumor responses in prostate cancer Ge Song, Aiying Xiong, Seng Zhu, Xuemei Tian, Xiaoling Yuan, Wanli Zhang, Wan-Jen Yang, Xiansong Xiong, Ling Ding, Haixiang Yu, Xiaoli Hou, Pingao Yan, Qingyu Wang, Xiao Zou, Chen Hu, Jijun Yuan
• 5399 QLS2309, a trifunctional NKp46/CD16a-NK cell engager targeting CD70 enhances efficacy against acute myeloid leukemia via mitigating the refraction to therapeutic antibody-dependent cytotoxicity Liuqing Yang, Ruimei Li, Xiaoran Wu, Shuyong Zhao, Hua Ying, Weikang Tao
• 5400 QLS2313, a CD79b/CD20 tri-specific T cell engager with dual-targeting strategy developed as a new therapeutics for the treatment of DLBCL Ting Lu, Liuqing Yang, Fujia Yao, Dongdong Wu, Shuyong Zhao, Hua Ying, Weikang Tao
• 5401 A novel bispecific ADC targeting Nectin-4 and HER2 demonstrates superior and broad antitumor efficacy in preclinical models Jinxiu Hou, Tingting Gu, Chuan Chen, Chenpeng Su, Xiaoqian Chen, Dandan Liu, Jiyuan Tian, Zhihang Liu, Yongxin Shang, Rongmei Yan, Kezhen Ye, Liang Tian, Jian Peng, Zhenping Zhu
• 5402 · PDF Engineering and development of a novel bispecific ADC targeting EGFR and FGFR2b Liang Zhu, Chuan Chen, Chenpeng Su, Mei Tian, Xiaoqian Chen, Dandan Liu, Jiyuan Tian, Yang He, Yongxin Shang, Rongmei Yan, Kezhen Ye, Liang Tian, Jian Peng, Zhenping Zhu
• 5404 Tumor cell targeted granzyme B demonstrates direct cytotoxic action and indirect immunogenic cell death mediated through numerous defined proteins Khalid A. Mohamedali, Madhuri Wadehra, Lawrence H. Cheung, Michael G. Rosenblum
• 5405 STX002: A GPC3-targeted antibody-drug conjugate with potent and durable antitumor activity in preclinical models of hepatocellular carcinoma Deepak Rohila, Sameena Wani, Atul Tandon, Jianhua Zhao, Anindya Bagchi, Ashutosh Tiwari
• 5406 A novel AI-engineered biparatopic DLL3/CD3 T cell engager demonstrates potent preclinical efficacy and a promising safety profile Chuan Chen, Yue Wu, Chenpeng Su, Dandan Liu, Jiyuan Tian, Yujuan Li, Yongxin Shang, Xiaoqian Chen, Rongmei Yan, Liang Tian, Jian Peng, Zhenping Zhu
• 5407 Mechanism of CAPRIN-1 membrane localization in cancer and development of TRK-950, a humanized anti-CAPRIN-1 antibody Yoshitaka Minamida, Shoichi Ohno, Kazushi Tachibana, Ukei Wasai, Takayuki Fujita, Takashi Morimoto, Fumiyoshi Okano

在完整检索应用中浏览本分会场 →